
ALDX Valuation
Aldeyra Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings
ALDX Relative Valuation
ALDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ALDX is overvalued; if below, it's undervalued.
Historical Valuation
Aldeyra Therapeutics Inc (ALDX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.12 is considered Undervalued compared with the five-year average of -8.18. The fair price of Aldeyra Therapeutics Inc (ALDX) is between 2575.34 to 2580.76 according to relative valuation methord. Compared to the current price of 5.44 USD , Aldeyra Therapeutics Inc is Undervalued By 99.79%.
Relative Value
Fair Zone
2575.34-2580.76
Current Price:5.44
99.79%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
5.22
P/B
Median3y
2.79
Median5y
2.97
-14.24
FCF Yield
Median3y
-15.32
Median5y
-14.28
Competitors Valuation Multiple
The average P/S ratio for ALDX's competitors is 16714.71, providing a benchmark for relative valuation. Aldeyra Therapeutics Inc Corp (ALDX) exhibits a P/S ratio of 8.12, which is -99.95% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch

ELMD
Electromed Inc
18.640
USD
-2.20%

BRBS
Blue Ridge Bankshares Inc
3.810
USD
-3.54%

FPH
Five Point Holdings LLC
6.430
USD
-0.46%

RGP
Resources Connection Inc
5.270
USD
-4.18%

RZLT
Rezolute Inc
5.870
USD
-0.17%

AVIR
Atea Pharmaceuticals Inc
3.740
USD
+7.16%

SMTI
Sanara Medtech Inc
25.650
USD
-6.32%

DOMO
Domo Inc
16.130
USD
0.00%

AQST
Aquestive Therapeutics Inc
4.200
USD
-1.41%

DSGN
Design Therapeutics Inc
4.040
USD
-5.39%
FAQ

Is Aldeyra Therapeutics Inc (ALDX) currently overvalued or undervalued?
Aldeyra Therapeutics Inc (ALDX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.12 is considered Undervalued compared with the five-year average of -8.18. The fair price of Aldeyra Therapeutics Inc (ALDX) is between 2575.34 to 2580.76 according to relative valuation methord. Compared to the current price of 5.44 USD , Aldeyra Therapeutics Inc is Undervalued By 99.79% .

What is Aldeyra Therapeutics Inc (ALDX) fair value?

How does ALDX's valuation metrics compare to the industry average?

What is the current P/B ratio for Aldeyra Therapeutics Inc (ALDX) as of Jul 25 2025?

What is the current FCF Yield for Aldeyra Therapeutics Inc (ALDX) as of Jul 25 2025?

What is the current Forward P/E ratio for Aldeyra Therapeutics Inc (ALDX) as of Jul 25 2025?
